LGND
Ligand Pharmaceuticals Incorporated
301.50$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.9% | 58.0% | 57.8% | 66.3% | 77.2% | -24.4% | 33.4% | 32.6% | 70.2% | 37.8% | 58.1% | 18.4% | |
| 4.1% | 3.7% | 10.4% | 8.3% | 5.9% | 36.4% | 17.1% | 21.1% | 26.2% | 27.8% | 21.1% | 13.3% | |
| 17.5% | 17.3% | 17.3% | 17.7% | 8.3% | 20.4% | 18.8% | 16.1% | 30.7% | 19.6% | 24.6% | 17.5% | |
| 14.7% | -280.6% | 49.4% | 51.9% | 3.6% | -596.8% | -1.1% | 2.6% | 24.4% | – | – | – | |
| -17.0% | 1.1% | -9.7% | -8.1% | -15.5% | -3.5% | -6.2% | -21.6% | 33.5% | -26.2% | 11.6% | -4.7% | |
| 7.0% | 15.1% | 26.0% | 5.1% | 4.7% | 2.1% | 2.7% | 3.6% | 9.1% | 41.0% | 11.8% | 0.2% | |
| -3.1% | -156.9% | -131.4% | -59.7% | -168.3% | 388.2% | 141.6% | 12.6% | 83.4% | -8.9% | -86.0% | -140.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 2.5% | 1.8% | 6.3% | 2.5% | – | – | – | |
| -105.3% | -0.7% | -3.6% | -1.4% | -48.9% | -376.7% | -47.7% | -7.6% | -4.2% | -3.5% | -3.1% | -5.6% | |
| -30.3% | 740.2% | 488.5% | 377.3% | 205.0% | -22.7% | -135.9% | -68.3% | -133.0% | -58.6% | 0.0% | 131.9% | |
| 201.5% | 11.6% | 1.4% | -5.3% | 130.7% | -403.4% | -189.9% | -57.0% | -140.6% | -45.7% | 58.1% | 159.7% | |
| 230.2% | -87.3% | -72.2% | 1.3% | 39.4% | -39.5% | -14.9% | -11.8% | 13.0% | -16.8% | 29.5% | 38.3% | |
| 24.9% | 42.9% | 31.8% | 61.2% | 72.4% | -26.5% | 30.6% | 29.0% | 61.1% | -3.3% | 46.3% | 18.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.